Skip to content
DataLookout
Menu

NCT06470048

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 19 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 106 → 96 locations
    • Enrollment target: 201 to 203
  2. Minor Enrollment closed, study ongoing
    • Trial sites reduced: 128 → 106 locations
    • Enrollment target: estimated 200 to confirmed 201
  3. Notable Eligibility criteria shortened, about 13 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Site details revised at 38 of 128 sites
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 4 words
  4. Minor Site details revised at 8 of 128 sitesv17
  5. Minor Site details revised at 19 of 128 sitesv16
  6. Minor Site details revised at 42 of 128 sitesv15
  7. Minor Study completion pushed from Jul 15, 2030 to Jul 31, 2034
    • Study sites: 127 to 128
    • Primary completion date: Jul 6, 2027 to Jul 30, 2027
    v14
  8. Minor Study sites: 120 to 127v13
  9. Notable Primary completion date: Jul 10, 2028 to Jul 6, 2027
    • Study sites: 116 to 120
    v12
  10. Minor Study sites: 109 to 116v11
  11. Minor Study sites: 103 to 109v10
  12. Minor Study sites: 96 to 103v9
  13. Minor Study sites: 83 to 96v8
  14. Notable Eligibility criteria expanded, about 64 words
    • Study sites: 37 to 83
    v7
  15. Minor Study sites: 26 to 37v6
  16. Minor Study sites: 10 to 26v5
  17. Minor Study sites: 1 to 10
    • Start date changed from estimate of Jul 31, 2024 to Oct 9, 2024
    v3
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  19. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

3/5 rCRISS25 response
Timeframe: Week 52

Secondary (6)

Change from baseline in FVC% predicted at Week 52
Change from baseline in mRSS at Week 52
Change from baseline in HAQ-DI at Week 52
Ianalumab concentrations in serum during treatment and Follow-up Period
Incidence and titer of anti-drug (ianalumab) antibodies (ADAs) in serum over time
Show 1 moreShow less
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Arms and interventions

VAY736 (Ianalumab)Experimental

Treatment Period 1: Ianalumab subcutaneous (s.c.) injection as defined in the protocol Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

PlaceboPlacebo comparator

Treatment Period 1: Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

Drugs: Placebo, Ianalumab

Sites

96 sites in 25 countries

United States 14, Japan 10, Italy 7, China 6, Colombia 6, Brazil 5, India 5, Argentina 4, France 4, Mexico 4, Taiwan 4, Greece 3, South Korea 3, Spain 3, Germany 2, Hungary 2, Malaysia 2, Poland 2, Thailand 2, United Kingdom 2, Vietnam 2, Austria 1, Belgium 1, Portugal 1, Turkey (Türkiye) 1